Tysabri Reimbursement Is Not Restricted By One-Year Data, Biogen Idec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec/Elan have held discussions with 700 payors in an effort to minimize reimbursement barriers for the recently approved multiple sclerosis therapy; another 1,000 are planned. The companies expect to release two-year data from the pivotal trials next year.